Opendata, web and dolomites

mABSPN SIGNED

Antibody-based therapy against Streptococcus pneumoniae

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "mABSPN" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Organization address
address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX
website: www.umcutrecht.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 165˙598 €
 EC max contribution 165˙598 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-06-15   to  2020-06-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) coordinator 165˙598.00

Map

 Project objective

The pneumococcus (Streptococcus pneumoniae) is the predominant cause of community-acquired pneumonia and causes otitis media, sinusitis, meningitis and sepsis. The increased serotype replacement and antibiotic resistance, reinforces the necessity of developing alternative treatment strategies for this pathogen. Monoclonal antibodies that boost the host immune system are attractive candidates to fight the high rates of morbidity and mortality due to this important human pathogen. Antibodies recognizing bacterial surface structures could be used to trigger activation of the complement cascade and subsequent bacterial killing. However, no significant progress has been made in the direction of immune system boosting therapies against pneumococci, mainly caused by our limited insights into antibody-driven immune activation on bacteria. With this proposal, I aim to study whether complement-enhancing monoclonal antibodies can be used as treatment against pneumococci. Through a combination of advanced sequencing approaches and functional complement activation assays, I will first identify antibodies against S. pneumoniae driving potent complement activation. Then I will use my expertise in S. pneumoniae infection models to unravel whether monoclonal antibodies eliciting complement are effective in pneumococcal killing in vitro and in vivo. The work proposed represents a first systematic approach to design effective therapeutic antibodies against S. pneumoniae that function via enhanced complement activation. Altogether, a better understanding of antibody-dependent complement activation on bacteria will create new avenues for the design of new therapeutic strategies to improve both antibody therapies and vaccination strategies in diseases caused by pathogenic bacteria.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MABSPN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MABSPN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

LYSOKIN (2020)

Architecture and regulation of PI3KC2β lipid kinase complex for nutrient signaling at the lysosome

Read More  

APTAFRAME (2019)

DNA-origami frame platform for co-evolution ligand selection

Read More  

EcoSpy (2018)

Leveraging the potential of historical spy satellite photography for ecology and conservation

Read More